
Novel immune checkpoint‐based immunotherapies may benefit specific groups of prostate cancer patients who are resistant to other treatments. We analyzed by immunohistochemistry the expression of B7‐H3, PD‐L1/B7‐H1, and androgen receptor (AR) in tissue samples from 120 prostate adenocarcinoma patients treated with radical prostatectomy in Spain, and from 206 prostate adenocarcinoma patients treated with radical prostatectomy in Norway...
Like
Save
Share